Explore the latest developments concerning Weight loss drug.
newsGP – Wegovy recommended for PBS listing
The PBAC recommended it be listed for adults with established cardiovascular disease with obesity, while also identifying which groups could have more affordable access to GLP-1s.
Semaglutide (sold as Wegovy) is now a significant step closer to being added to the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease with obesity.
It comes after the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing at its November meeting, releasing its decision late on Friday.
‘Patients must have already experienced a cardiovascular event such as a heart attack, stroke, or have symptomatic peripheral arterial disease,’ PBAC said.
‘To best reach patients at high risk and considering the high cost of treatment, the PBAC determined it would be appropriate to limit PBS access to people with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for people of Asian, Aboriginal, or Torres Strait Islander ethnicity.’
The cost barrier to some Australians accessing weight-loss drugs more broadly could also soon be lifted following new PBAC advice to the health minister.
At the request of Federal Health and Ageing Minister Mark Butler, the PBAC undertook a comprehensive review of glucagon-like peptide-1 (GLP-1) receptor agonist medicines for obesity, focussing on equitable access.
The PBAC has now released its recommendation on which groups should be prioritised to ensure ‘equitable subsidised access to GLP-1 for the treatment of obesity’.
‘Based on current evidence’, the PBAC considered this should include:
Pink Lace Front Wig Human Hair For Women 13×4 Hd Lace Frontal Wig Brazilian 613 13×6 Colored Straight Lace Front Wigs
The dynamic landscape of current events often brings forth significant discussions. Monitoring these developments provides crucial insights.
For more detailed information, explore updates concerning Weight loss drug.
Leave a Reply